TRANSCEND-T2D-1 (NCT06354660)

Phase 3, randomised, multicentre, double-blind study of retatrutide (once weekly) versus placebo in adults with type 2 diabetes and inadequate glycaemic control on diet and exercise alone — a treatment-naive, first-line diabetes population, distinct from TRIUMPH-2’s obesity-plus-T2D population. Status: completed (actual completion 2026-02-20); no structured results record posted to ClinicalTrials.gov yet, and no topline figures are verified for publication on this Record.